Pregnancy-Related Deaths in the US A CDC cross-sectional national study showed an increase in pregnancy-related deaths in the US from 2018 to 2022, with highest rates among American Indian, Alaska Native women, and non-Hispanic Black women. https://t.co/H1s649GyiL https://t.co/MXnrQrAcrT

• Pregnancy-Related Deaths in the US | RheumNow

ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer Pain The American College of Physicians published a best practice advisory on cannabis or cannabinoids in the Annals of Internal Medicine. https://t.co/B0eWstjN0Z https://t.co/IzSEIeosme

• ACP: Best Practice Advice on Cannabis or Cannabinoids Use for Chronic Noncancer…

"Don’t ever let anyone tell you you ain’t strong enough" – Janis Joplin https://t.co/1B1YD5gDLk

Uveitis Risk with Slow Adalimumab Weaning Patients with pediatric non-infectious uveitis (NIU) who achieved remission on adalimumab (Humira) had lower recurrence rates when the drug was withdrawn more gradually, a retrospective cohort analysis indicated. https://t.co/KgQsK6fVnr

2nd Opinions in Rheumatology https://t.co/R4CjJHEaL4 https://t.co/0quDwdANyU

• 2nd Opinions in Rheumatology | RheumNow

Vamorolone: a New Steroid on the Horizon? Vamorolone is a potentially new alternative to traditional glucocorticoids for use in inflammatory diseases. It is a dissociated steroidal compound with reduced side effects, and in an animal model of inflammation has shown effective https://t.co/38WTOAuuJy

Summary of the updated BSR Axial Spondyloarthritis for biological and targeted synthetic DMARD guidelines 2025 @RheumatologyUK #axialspondyloarthritis Full paper available at: https://t.co/LytDiHjawi https://t.co/iaHzD1BQRe

• The 2025 British Society for Rheumatology guideline for the treatment of axial …
• https://x.com/synovialjoints/status/1910066875406443007/photo/1

📢Calling all paediatrics! #BSR25 is almost here - Check out our top paediatric highlights from a packed Annual Conference programme 🔗Read our latest blog now: https://t.co/8uJMiqg2fW https://t.co/PAASNk3ZuF

• Paediatric highlights at this year’s Annual Conference:
• https://x.com/RheumatologyUK/status/1910597457194410098/photo/1

Prof Ian Giles will be covering a range of topics at this year's Rheumapreg Conference such as how immunologic changes and placental dysfunction cause adverse outcomes in rheumatic disease pregnancies. View the full prgramme and learn more: https://t.co/tjiycjKJ8i https://t.co/FugHvtm8fY

• RheumaPreg 2025
• https://x.com/RheumatologyUK/status/1910646278435840168/photo/1

In our latest episode, @deodhara takes us behind the scenes of his research on IV secukinumab in #AxSpA. Discover key findings from the INVIGORATE-1 study, how it’s shaping treatment options, & what’s next in AxSpA research. LISTEN NOW → https://t.co/2IBixQSdpO @ACR_Journals https://t.co/HzcJw0pzWI

• ACR Journals On Air: IV Secukinumab for Axial Spondyloarthritis
• https://x.com/ACRheum/status/1910780161647059171/photo/1

43 days to the Lupus Congress 2025 in Toronto 🦋...see you soon! Abstract Sessions, Poster Tour Presentations, Plenary Sessions, Scientific Sessions, Debate Sessions, Patient Sessions, Fishbowl Discussion, and GALA DINNER on May 23!!! @LupusCongress https://t.co/MaWjyofnIz

• https://twitter.com/LupusCongress/status/1908177010066665543

Bimekizumab efficacy and safety in patients with psoriatic arthritis who had skin and nail psoriasis at baseline: Up to 2-year results from two phase 3 studies Sponsored by UCB https://t.co/461bFRZwjw

• Bimekizumab efficacy and safety in patients with psoriatic arthritis who had sk…

Sjogrens is a hot area in drug development: “Sjogren’s Syndrome Pipeline Insight 2025” report provides comprehensive insights about 20+ companies and 22+ pipeline drugs, including: nipocalimab VAY736 (ianalumab) HZN-1116 AMG 329 R-2487 https://t.co/sVbyPLi2Um https://t.co/IlvthM7qyG

• https://buff.ly/ucJRICC

Patient info on Sweets Syndrome: acute febrile neutrophilic dermatosis https://t.co/0q93q2NVc9 https://t.co/cE3LA8LaRQ

• Sweet’s Syndrome

RA Prevention through Deep Immunophenotyping Researchers at the University of Colorado have identified pathogenic immune phenotypes in at-risk populations for RA. They have found the expansion of specific T cell subtypes, in the at-risk group, and postulate this could lead to https://t.co/AEo0GOr7Kn